Dysregulated Amino Acid Sensing Drives Colorectal Cancer Growth and Metabolic Reprogramming Leading to Chemoresistance

被引:30
|
作者
Solanki, Sumeet [1 ]
Sanchez, Katherine [1 ]
Ponnusamy, Varun [1 ]
Kota, Vasudha [1 ]
Bell, Hannah N. [1 ]
Cho, Chun-Seok [1 ]
Kowalsky, Allison H. [1 ]
Green, Michael [1 ,2 ,3 ]
Lee, Jun Hee [1 ]
Shah, Yatrik M. [1 ,3 ,4 ,5 ,6 ]
机构
[1] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI USA
[2] Univ Michigan, Dept Radiat Oncol & Microbiol & Immunol, Ann Arbor, MI USA
[3] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA
[4] Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI USA
[5] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA
[6] Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA
关键词
mTORC1; Depdc5; Wdr24; Sestrin; 2; 5-Fluorouracil; MTORC1; NUTRIENT; COMPLEX; RESTRICTION; PATHWAY; GTPASES; TARGET;
D O I
10.1053/j.gastro.2022.11.014
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Colorectal cancer (CRC) is a devastating disease that is highly modulated by dietary nutrients. Mechanistic target of rapamycin complex 1 (mTORC1) contributes to tumor growth and limits therapy responses. Growth factor signaling is a major mechanism of mTORC1 activation. However, compensatory pathways exist to sustain mTORC1 activity after therapies that target oncogenic growth factor signaling. Amino acids potently activate mTORC1 via amino acid-sensing GTPase activity towards Rags (GATOR). The role of amino acid-sensing pathways in CRC is unclear. METHODS: Human colon cancer cell lines, preclinical intestinal epithelial-specific GATOR1 and GATOR2 knockout mice subjected to colitis-induced or sporadic colon tumor models, small interfering RNA screening targeting regulators of mTORC1, and tissues of patients with CRC were used to assess the role of amino acid sensing in CRC. RESULTS: We identified loss-of -function mutations of the GATOR1 complex in CRC and showed that altered expression of amino acid-sensing pathways pre-dicted poor patient outcomes. We showed that dysregulated amino acid-sensing induced mTORC1 activation drives colon tumorigenesis in multiple mouse models. We found amino acid- sensing pathways to be essential in the cellular reprogramming of chemoresistance, and chemotherapeutic-resistant patients with colon cancer exhibited de-regulated amino acid sensing. Limiting amino acids in in vitro and in vivo models (low-protein diet) reverted drug resistance, revealing a metabolic vulnerability. CONCLUSIONS: Our findings suggest a critical role for amino acid-sensing pathways in driving CRC and highlight the trans-lational implications of dietary protein intervention in CRC.
引用
收藏
页码:376 / +
页数:29
相关论文
共 50 条
  • [21] Metabolic reprogramming in colorectal cancer: regulatory networks and therapy
    Jieping Zhang
    Shaomin Zou
    Lekun Fang
    Cell & Bioscience, 13
  • [22] Reprogramming of amino acid transporters induces Aspartate and Glutamate dependency and drives endocrine resistance in breast cancer
    Bacci, Marina
    Lorito, Nicla
    Ippolito, Luigi
    Ramazzotti, Matteo
    Parri, Matteo
    Simoes, Bruno M.
    Martin, Lesley-Ann
    Marangoni, Elisabetta
    Mazzone, Massimiliano
    Chiarugi, Paola
    Morandi, Andrea
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 539 - 540
  • [23] Triterpenoid ursolic acid drives metabolic rewiring and epigenetic reprogramming in treatment/prevention of human prostate cancer
    Li, Shanyi
    Wu, Renyi
    Wang, Lujing
    Dina Kuo, Hsiao-Chen
    Sargsyan, Davit
    Zheng, Xi
    Wang, Yujue
    Su, Xiaoyang
    Kong, Ah-Ng
    MOLECULAR CARCINOGENESIS, 2022, 61 (01) : 111 - 121
  • [24] Branched chain amino acid metabolic reprogramming in heart failure
    Sun, Haipeng
    Wang, Yibin
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2016, 1862 (12): : 2270 - 2275
  • [25] Metabolic reprogramming drives homeostasis and specialization of regulatory T cells in cancer
    Le Li
    Zezhong Xiong
    Zhiquan Hu
    Xing Zeng
    Zhihua Wang
    Oncology and Translational Medicine, 2022, 8 (01) : 18 - 27
  • [26] Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer
    Malier, Marie
    Gharzeddine, Khaldoun
    Laverriere, Marie-Helene
    Marsili, Sabrina
    Thomas, Fabienne
    Decaens, Thomas
    Roth, Gael
    Millet, Arnaud
    CANCER RESEARCH, 2021, 81 (23) : 5963 - 5976
  • [27] METABOLIC REPROGRAMMING TO ENHANCE THE EFFICACY OF MTOR INHIBITION IN COLORECTAL CANCER
    Klauck, P. J.
    Weber, M.
    Pitts, T. M.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2018, 66 (01) : 109 - 109
  • [28] Recent advances microRNAs and metabolic reprogramming in colorectal cancer research
    Xiong, Bin
    Huang, Qiaoyi
    Zheng, Huida
    Lin, Shu
    Xu, Jianhua
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] Metabolic reprogramming enhances the efficacy of mTOR inhibition in colorectal cancer
    Klauck, Peter J.
    Hawkins, Hayley J.
    Weber, Madison
    Bagby, Stacey M.
    Lieu, Christopher H.
    Hartman, Sarah J.
    Yacob, Betelehem W.
    Sullivan, Kelly D.
    Brown, Monica
    Reisz, Julie A.
    D'Alessandro, Angelo
    Messersmith, Wells A.
    Eckhardt, S. Gail
    Pitts, Todd M.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [30] Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer
    Hutton, Josiah E.
    Wang, Xiaojing
    Zimmerman, Lisa J.
    Slebos, Robbert J. C.
    Trenary, Irina A.
    Young, Jamey D.
    Li, Ming
    Liebler, Daniel C.
    MOLECULAR & CELLULAR PROTEOMICS, 2016, 15 (09) : 2924 - 2938